Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-09-26

Clinical Trial Update: Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics [NA]

View source ↗

Summary

This clinical trial update reports on how CYP2B6 genetic polymorphisms affect the pharmacokinetics of efavirenz in HIV patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EFAVIRENZ (efavirenz)

Snippet

Sponsor: Indiana University | Conditions: HIV | NA | Status: COMPLETED | Results posted: 2014-09-26